Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 degrader for extensive evaluation for the treatment of human cancers and other human diseases.
Authors
- D. H. Sun (ORCID: https://orcid.org/0000-0001-6578-5142)
- S Wang
- Meilin Wang (ORCID: https://orcid.org/0000-0003-4509-9561)
- Ranjan Kumar Acharyya (ORCID: https://orcid.org/0000-0002-1562-0216)
- Rohan Kalyan Rej (ORCID: https://orcid.org/0000-0003-0904-9137)
- Jelena Tošović (ORCID: https://orcid.org/0000-0001-5531-7193)
- Hoda Metwally
- Donna McEachern (ORCID: https://orcid.org/0000-0001-8662-3425)
- Bo Wen (ORCID: https://orcid.org/0000-0003-2287-473X)
- Haibin Zhou (ORCID: https://orcid.org/0000-0003-0879-790X)
- Dimin Wu
- Longchuan Bai
- Mi Wang
Institutions
- University of Michigan (US)
- Medicina (PL)
- Rogers (United States) (US)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03767
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00